QuidelOrtho Reports Significant Q1 Miss and Lowers Full-Year 2026 Financial Guidance
QDEL is trading near its 52-week low of $10.86 (6.1% above the low).
Summary
QuidelOrtho announced a significant miss for its first-quarter financial results and lowered its full-year 2026 guidance across all key financial metrics, citing a weak respiratory season and market disruptions.
Key Events · Earnings and Guidance · QDEL
-
Q1 Financial Results Miss Expectations
Total revenue for Q1 2026 was $620 million, a 10.5% decline from $692.8 million in Q1 2025. GAAP net loss widened to $92 million from $12.7 million in the prior year, and adjusted diluted loss per share was $0.04 compared to a $0.74 gain in Q1 2025.
-
Full-Year 2026 Guidance Significantly Lowered
The company updated its full-year 2026 guidance, reducing expected total revenues, adjusted EBITDA, adjusted EBITDA margin, adjusted diluted earnings per share (from $2.00-$2.42 to $1.80-$2.00), and free cash flow (from $120-$160 million to $100-$120 million).
-
Operational Challenges Cited
The weaker performance and guidance revision are attributed to a significantly weaker respiratory season, slower distributor sales in China due to pending IVD pricing guidelines, and business disruption related to the Middle East conflict.
-
Strategic Initiatives for Future Growth
Despite current challenges, the company completed the acquisition of LEX Diagnostics and launched key products like the High-Sensitivity Troponin assay and VITROS 450 platform, aiming to drive sustainable long-term growth.
Analysis · QDEL · Life Sciences
QuidelOrtho reported first-quarter results that significantly missed expectations, with total revenue declining by 10.5% year-over-year and GAAP net loss widening substantially. The company also lowered its full-year 2026 financial guidance across all key metrics, including revenue, adjusted EBITDA, adjusted diluted EPS, and free cash flow. This downward revision reflects a weaker respiratory season, business disruptions in China due to pending IVD pricing guidelines, and impacts from the Middle East conflict. While the company highlighted the recent LEX Diagnostics acquisition and new product launches as future growth drivers, the immediate financial outlook has deteriorated, indicating ongoing operational challenges following a significant net loss in the prior fiscal year.
At the time of this filing, QDEL was trading at $11.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $793.8M. The 52-week trading range was $10.86 to $38.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.